VEGF mediates apoE4-induced neovascularization and synaptic pathology in the choroid and retina

Current Alzheimer Research

Volumn 12, Issue 4, 2015, Pages 323-334

  Antes, Ran ^a   Salomon Zimri, Shiran ^a   Beck, Susanne C ^b   Garrido, Marina Garcia ^b   Livnat, Tami ^c   Maharshak, Idit ^a   Kadar, Tamar ^d   Seeliger, Mathias ^b   Weinberger, Dov ^c   Michaelson, Daniel M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c RABIN MEDICAL CENTER   (Israel)

^d ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Alzheimer's disease; Apolipoprotein E4 (apoE4); Choroid; Neovascolarization; Retina; Synapses; Targeted replacement mice; VEGF

Indexed keywords

APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE SYNTHASE; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CHOROID VASCULARIZATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; FLUORESCENCE MICROSCOPY; FRACTIONAL ANISOTROPY; GENOTYPE; IN VIVO STUDY; LOW LEVEL LASER THERAPY; MALE; MOUSE; MUELLER CELL; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA ANGIOGRAPHY; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; RETINITIS; SCANNING LASER OPHTHALMOSCOPY; SCAR; SUBRETINAL NEOVASCULARIZATION; SYNAPSE; ALZHEIMER DISEASE; ANIMAL; ASTROCYTE; C57BL MOUSE; CHOROID; DISEASE MODEL; GENETICS; MACROGLIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; TRANSGENIC MOUSE; VASCULARIZATION;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ASTROCYTES; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; EPENDYMOGLIAL CELLS; GLIAL FIBRILLARY ACIDIC PROTEIN; MICE, INBRED C57BL; MICE, TRANSGENIC; RETINA; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; SYNAPSES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929616085     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150325182504     Document Type: Article

References (57)

1. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 49(2): 338-49 (1991).
2. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (New York, NY) 261(5123): 921-3 (1993).
3. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90(5): 1977-81 (1993).
4. Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 48(1): 139-47 (1997).
5. Mahley RW, Huang Y. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 76(5): 871-85 (2012).
6. Maloney B, Ge YW, Petersen RC, Hardy J, Rogers JT, Perez-Tur J, et al. Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions. American journal of medical genetics Part B, Neuropsychiatric genetics : Int Soc Psych Genet 153B(1): 185-201 (2010).
7. Kutner KC, Erlanger DM, Tsai J, Jordan B, Relkin NR. Lower cognitive performance of older football players possessing apolipoprotein E epsilon4. Neurosurgery 47(3): 651-7; discussion 57-8 (2000).
8. Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 17(2): 516-29 (1997).
9. Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, Hirono N, et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol 51(2): 209-14 (2002).
10. Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? Neuron 81(4): 740-54 (2014).
11. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90(20): 9649-53 (1993).
12. Lehtovirta M, Soininen H, Laakso MP, Partanen K, Helisalmi S, Mannermaa A, et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. J Neurol, Neurosurg Psych 60(6): 644-9 (1996).
13. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and betaamyloid peptides. Nat Genet 14(1): 55-61 (1996).
14. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106(16): 6820-5 (2009).
15. Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 70(4): 440-4 (2013).
16. Jellinger KA. Morphologic diagnosis of "vascular dementia" - a critical update. J Neurol Sci 270(1-2): 1-12 (2008).
17. Yin YW, Li JC, Wang JZ, Li BH, Pi Y, Yang QW, et al. Association between apolipoprotein E gene polymorphism and the risk of vascular dementia: a meta-analysis. Neurosci Lett 514(1): 6- 11 (2012).
18. de Knijff P, Havekes LM. Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach. Curr Opin Lipidol 7(2): 59-63 (1996).
19. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 53(6): 1308-11 (1999).
20. Bek T. Regional morphology and pathophysiology of retinal vascular disease. Prog Retin Eye Res 36: 247-59 (2013).
21. Antes R, Ezra-Elia R, Weinberger D, Solomon A, Ofri R, Michaelson DM. ApoE4 induces synaptic and ERG impairments in the retina of young targeted replacement apoE4 mice. PloS one 8(5): e64949 (2013).
22. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Investig 76(4): 1501-13 (1985).
23. Bojanowski CM, Shen D, Chew EY, Ning B, Csaky KG, Green WR, et al. An apolipoprotein E variant may protect against agerelated macular degeneration through cytokine regulation. Environ Mol Mutagen 47(8): 594-602 (2006).
24. Campochiaro PA. Ocular neovascularization. J Mol Med 91(3): 311-21 (2013).
25. Malek G, Johnson LV, Mace BE, Saloupis P, Schmechel DE, Rickman DW, et al. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci USA 102(33): 11900-5 (2005).
26. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935): 1306-9 (1989).
27. Licht T, Keshet E. Delineating multiple functions of VEGF-A in the adult brain. Cell Mol Life Sci 70(10): 1727-37 (2013).
28. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272(29): 17972-80 (1997).
29. Levi O, Jongen-Relo AL, Feldon J, Roses AD, Michaelson DM. ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Neurobiol Dis 13(3): 273-82 (2003).
30. Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, Falick AM, et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein science : Prot Soc 14(12): 3135- 9 (2005).
31. Narfstrom K, Vaegan, Katz M, Bragadottir R, Rakoczy EP, Seeliger M. Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs. Documenta ophthalmologica Adv Ophthalmol 111(1): 39-48 (2005).
32. Belinson H, Lev D, Masliah E, Michaelson DM. Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci 28(18): 4690-701 (2008).
33. Kurumada S, Onishi A, Imai H, Ishii K, Kobayashi T, Sato SB. Stage-specific association of apolipoprotein A-I and E in developing mouse retina. Investig Ophthalmol Vis Sci 48(4): 1815- 23 (2007).
34. Lorber B, Berry M, Douglas MR, Nakazawa T, Logan A. Activated retinal glia promote neurite outgrowth of retinal ganglion cells via apolipoprotein E. J Neurosci Res 87(12): 2645-52 (2009).
35. Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, Wu S, et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 32(5): 791-801 (2011).
36. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 120(1): 106-14 (2013).
37. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Develop Biol 48(8- 9): 1045-58 (2004).
38. Li X, Cai Y, Wang YS, Shi YY, Hou W, Xu CS, et al. Hyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stress-induced activation of STAT3 signalling in RPE cells. PloS one 7(10): e47600 (2012).
39. Huang H, Parlier R, Shen JK, Lutty GA, Vinores SA. VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PloS one 8(8): e71808 (2013).
40. Julien S, Kreppel F, Beck S, Heiduschka P, Brito V, Schnichels S, et al. A reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit. Mol Vis 14: 1358-72 (2008).
41. Wickremasinghe SS, Xie J, Lim J, Chauhan DS, Robman L, Richardson AJ, et al. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Investig Ophthal Vis Sci 52(7): 4072-9 (2011).
42. Kanoff J, Miller J. Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab. Sem Ophthal 28(5-6): 355-60 (2013).
43. Chiappelli M, Borroni B, Archetti S, Calabrese E, Corsi MM, Franceschi M, et al. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuven Res 9(4): 485-93 (2006).
44. Provias J, Jeynes B. Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. Curr Alzheimer Res 8(2): 197-202 (2011).
45. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 52(1): 131-45 (2008).
46. Huebbe P, Lodge JK, Rimbach G. Implications of apolipoprotein E genotype on inflammation and vitamin E status. Mol Nutr Food Res 54(5): 623-30 (2010).
47. Ramaswamy G, Xu Q, Huang Y, Weisgraber KH. Effect of domain interaction on apolipoprotein E levels in mouse brain. The Journal of neuroscience : J Soc Neurosci 25(46): 10658-63 (2005).
48. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 29(6): 500-19 (2010).
49. Jawad S, Liu B, Li Z, Katamay R, Campos M, Wei L, et al. The role of macrophage class a scavenger receptors in a laser-induced murine choroidal neovascularization model. Investig Ophthalmol Vis Sci 54(9): 5959-70 (2013).
50. Arcondeguy T, Lacazette E, Millevoi S, Prats H, Touriol C. VEGFA mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucl Acids Res 41(17): 7997-8010 (2013).
51. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89(2): 607-48 (2009).
52. Ma YY, Li KY, Wang JJ, Huang YL, Huang Y, Sun FY. Vascular endothelial growth factor acutely reduces calcium influx via inhibition of the Ca2+ channels in rat hippocampal neurons. J Neurosci Res 87(2): 393-402 (2009).
53. Meissirel C, Ruiz de Almodovar C, Knevels E, Coulon C, Chounlamountri N, Segura I, et al. VEGF modulates NMDA receptors activity in cerebellar granule cells through Src-family kinases before synapse formation. Proc Natl Acad Sci USA 108(33): 13782-7 (2011).
54. Klettner A, Kauppinen A, Blasiak J, Roider J, Salminen A, Kaarniranta K. Cellular and molecular mechanisms of age-related macular degeneration: from impaired autophagy to neovascularization. Int J Biochem Cell Biol 45(7): 1457-67 (2013).
55. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 237: 1-30 (1999).
56. Huang H, Shen J, Vinores SA. Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. PloS one 6(6): e21411 (2011).
57. Gu L, Chen H, Tuo J, Gao X, Chen L. Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA. Exp Eye Res 91(3): 433-9 (2010).